Societe Generale downgraded shares of Fresenius Medical Care AG & Co. (NYSE:FMS) from a buy rating to a hold rating in a research note issued to investors on Thursday morning, TheFlyOnTheWall.com reports.

Other equities analysts also recently issued research reports about the stock. Commerzbank AG downgraded shares of Fresenius Medical Care AG & Co. to a hold rating in a research note on Friday, May 29th. RBC Capital raised their price target on shares of Fresenius Medical Care AG & Co. from $35.00 to $40.00 and gave the company a sector perform rating in a report on Friday, July 31st. Seven research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. The company has a consensus rating of Hold and a consensus target price of $41.10.

Shares of Fresenius Medical Care AG & Co. (NYSE:FMS) traded up 0.91% during trading on Thursday, hitting $41.15. 78,366 shares of the company were exchanged. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34. The stock has a market cap of $25.07 billion and a P/E ratio of 23.66. The company’s 50-day moving average price is $42.19 and its 200 day moving average price is $41.48.

Fresenius Medical Care AG & Co. (NYSE:FMS) last posted its quarterly earnings results on Thursday, July 30th. The company reported $0.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.42 by $0.02. During the same quarter in the prior year, the company posted $0.42 earnings per share. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.13 billion. The firm’s revenue for the quarter was up 15.0% compared to the same quarter last year. On average, equities analysts predict that Fresenius Medical Care AG & Co. will post $1.77 earnings per share for the current fiscal year.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...